Slide 1: FY25 Results Presentation
NASDAQ: IMRN ASX: IMC FY25 Results Presentation Steven Lydeamore Chief Executive Officer 29 August 2025
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 3: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Three commercial products: Travelan® (traveller’s diarrhoea), Prote
Slide 4: 1. Financial & Operational Highlights
1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 5: FY25 Financial Summary
FY25 Financial Summary Global Sales Australian Sales North American Revenue Revenue Sales Revenue $7.3m $5.3m $2.0m Up 49% Up 40% Up 76% EBITDA (ex-R&D)1 Cash + Term Gross Profit Deposit $(3.1)m Margin $5.9m (excludes $2.1m 65.4% A$2.8m raised from improvement the US placement)2 1 ex-R&D: add back r
Slide 6: Travelan continued strong sales growth
Travelan® continued strong sales growth Global Year to Date Net Sales ($AUD) Global $8,000,000 $7,000,000 $6,000,000 + FY2025 AUD$7.3 million up 49% on prior year $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000 $- Jul - Sep Oct - Dec Jan - Mar Apr - Jun Australia FY24 FY25 + FY2025 AUD$5.2 mi
Slide 7: Commercial – Operational Highlights
Commercial – Operational Highlights 2H FY25 and 1H FY24 2H FY24 1H FY25 Outlook Travelan® / Protectyn® • $2.36m global sales • $2.55m global sales • $4.00m global sales • $3.29m global sales Revenue • $1.87m Australia • $1.87m Australia • $2.89m Australia • $2.36m Australia • $0.48m North America •
Slide 8: 2. Clinical Development Program
2. CLINICAL DEVELOPMENT PROGRAM
Slide 9: Revenue generating with a strong clinical development pipeline
Revenue generating with a strong clinical development pipeline Indication 30 August 2024 29 August 2025 Travelan® (IMM-124E) Phase 2 Clinical study topline data reported in Clinical study report submitted to FDA in January 2025 March 2024 Awaiting Travelan® Uniformed Services University clinical tri
Slide 10: Status of product portfolio and key milestones
Status of product portfolio and key milestones Peak U.S. Collaborator or Funding Current Anticipated Dates Indication Compound Preclinical Phase 1 Phase 2 Phase 3 Registration sales Source Status 2H 2025 1H 2026 Uniformed 100% of 866 Traveller's Diarrhoea Travelan® US$ 102 m Services participants To
Slide 11: 3. Upcoming Milestones & Outlook
3. UPCOMING MILESTONES & OUTLOOK
Slide 12: Upcoming Milestones & Outlook
Upcoming Milestones & Outlook Commercial + Continued quarter on quarter growth of Travelan® from growth drivers + Australian launch of ProIBS in Q1 CY2026 + Planned growth in profitability1 of Hyperimmune products net of planned increased investment in selling & marketing Clinical IMM-124E (Travelan
Slide 13: Steven Lydeamore, Chief Executive Officer, Immuron Limited
STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172